Rovati L C, Pavelka K, Giacovelli G, Reginster J-Y
Department of Clinical Pharmacology, Rotta Research Laboratorium, Monza, Italy.
Osteoarthritis Cartilage. 2006;14 Suppl A:A14-8. doi: 10.1016/j.joca.2006.02.022. Epub 2006 May 5.
Knee pain relief has been suggested to potentially alter radioanatomic positioning in conventional standing antero-posterior knee radiographs. This study was performed to determine whether this is always the case and in particular if it applied to two recent randomised, placebo-controlled trials showing both symptom- and structure-modification with glucosamine sulfate in knee osteoarthritis.
Patients in the two studies were selected if they completed the 3-year evaluations and, irrespectively of treatment, (1) were pain-improvers in that they underwent Western Ontario and McMaster Universities (WOMAC) osteoarthritis index (WOMAC) pain decrease at least equal to the mean improvement observed with glucosamine sulfate, or (2) if their baseline standing knee pain (item #5 of the WOMAC pain scale) was "severe" or "extreme" and improved by any degree at the end of the trials. Changes in minimum joint space width were then compared between treatments.
Knee pain was of mild-to-moderate severity in the two original studies and in all patient subsets identified here. Obviously, there were more pain-improvers in the glucosamine sulfate than in the placebo subsets (N=76 vs 57 in pooling the two studies), but WOMAC pain scores improved to the same extent (over 50% relative to baseline). Notwithstanding such a major pain relief, patients in the placebo subsets of both studies suffered a definite mean (SE) joint space narrowing, that was of -0.22 (0.15)mm in the pooled analysis, and that was not observed with glucosamine sulfate: +0.15 (0.07)mm; P=0.003. Similar evidence was found in the smaller subsets with at least severe baseline standing knee pain improving after 3 years.
Knee pain relief did not bias the report of a structure-modifying effect of glucosamine sulfate in two recent long-term trials, possibly due to the mild-to-moderate patient characteristics. Consensus deliverables should acknowledge that the potential limitations of conventional standing antero-posterior radiographs should not be overestimated since they may not apply to all patient populations and to all studies using this gold standard technique.
有研究表明,缓解膝关节疼痛可能会改变传统站立位膝关节前后位X线片的放射解剖学定位。本研究旨在确定情况是否总是如此,特别是对于最近两项随机、安慰剂对照试验,这些试验显示硫酸葡萄糖胺对膝关节骨关节炎有症状和结构改善作用。
选择两项研究中完成3年评估的患者,无论治疗情况如何,(1)若患者疼痛改善,即其西部安大略和麦克马斯特大学骨关节炎指数(WOMAC)疼痛减轻至少等于硫酸葡萄糖胺观察到的平均改善程度;或(2)若其基线站立位膝关节疼痛(WOMAC疼痛量表第5项)为“重度”或“极重度”,且在试验结束时有所改善。然后比较各治疗组间最小关节间隙宽度的变化。
在两项原始研究及此处确定的所有患者亚组中,膝关节疼痛均为轻至中度。显然,硫酸葡萄糖胺组的疼痛改善患者比安慰剂组更多(两项研究合并后分别为N = 76和57),但WOMAC疼痛评分改善程度相同(相对于基线超过50%)。尽管疼痛得到了显著缓解,但两项研究安慰剂组的患者均出现了明确的平均(标准误)关节间隙变窄,合并分析中为-0.22(0.15)mm,而硫酸葡萄糖胺组未观察到这种情况:为+0.15(0.07)mm;P = 0.003。在较小的亚组中也发现了类似证据,这些亚组中至少有重度基线站立位膝关节疼痛的患者在3年后有所改善。
在最近两项长期试验中,膝关节疼痛缓解并未使硫酸葡萄糖胺结构改善作用的报告产生偏差,这可能是由于患者特征为轻至中度。共识性文件应承认,不应高估传统站立位前后位X线片的潜在局限性,因为它们可能不适用于所有患者群体以及所有使用这种金标准技术的研究。